Insider Trading May 4, 2026 04:23 PM

Cinemark Director Executes $4.43 Million Stock Sale via Pre-Arranged Trading Plan

Mark Zoradi disposes of 150,000 shares as Cinemark reports strong first-quarter financial performance.

By Marcus Reed CNK
Cinemark Director Executes $4.43 Million Stock Sale via Pre-Arranged Trading Plan
CNK

A recent regulatory filing has revealed that Mark Zoradi, a director at Cinemark Holdings, Inc. (NASDAQ:CNK), has completed a significant sale of company stock. On May 1, 2026, Zoradi disposed of 150,000 shares of common stock at a price point of $29.52 per share, resulting in total transaction proceeds of $4,428,000. This divestment was conducted indirectly through the Mark & Cathy Zoradi 96 Rev Trust.The transaction was not an ad-hoc decision but was carried out automatically under a Rule 10b5-1 trading plan that Mr. Zoradi had previously established on November 20, 2025. Following this movement of shares, Zoradi maintains an indirect ownership stake in Cinemark Holdings consisting of 286,608 shares. Since the date of the sale, the stock price has experienced a decline to $27.26, which represents a decrease of approximately 8% from the execution price of the transaction.

Key Points

  • The director's sale was executed through a pre-set Rule 10b5-1 plan established in November 2025.
  • Cinemark reported a massive 143% year-over-year increase in adjusted EBITDA for Q1 2026.
  • The company's revenue of $643.1 million exceeded market expectations by surpassing the $619.19 million forecast.

Insider Transaction Details

According to SEC Form 4 documentation, Cinemark Holdings, Inc. director Mark Zoradi executed the sale of 150,000 shares of common stock on May 1, 2026. The shares were sold at a price of $29.52 each, totaling $4,428,000 in value. This sale was facilitated through the Mark & Cathy Zoradi 96 Rev Trust. Following the completion of this transaction, Mr. Zoradi's indirect holdings in the company total 286,608 shares.

Notably, the filing indicates that this sell order was executed automatically pursuant to a Rule 10b5-1 trading plan. This specific plan had been adopted by Mr. Zoradi on November 20, 2025. Since the transaction took place, Cinemark's stock price has fallen to $27.26, marking an 8% drop from the level at which the shares were sold.


Recent Financial Performance and Market Position

Despite the insider sale, Cinemark Holdings recently announced robust financial results for the first quarter of 2026. The theater operator reported a year-over-year revenue increase of 19%, reaching $643.1 million. This figure outperformed the anticipated revenue of $619.19 million.

The company's profitability metrics also showed significant growth: adjusted EBITDA rose by 143% compared to the same period in the previous year. This result exceeded consensus expectations for adjusted EBITDA by 12.8%. Furthermore, Cinemark reported earnings per share (EPS) of -$0.06, which surpassed the forecasted -$0.13. This represents a positive EPS surprise of 53.85%.

In light of these results, Benchmark has maintained its Buy rating on the stock, setting a price target of $35.00. Analysts at the firm cited the company's strong first-quarter performance as a primary driver for this rating, noting that the data indicates a meaningful recovery and a positive financial trend for Cinemark.


Key Analytical Points

  • Automated Divestment: The sale was executed via a Rule 10b5-1 plan adopted in late 2025, indicating a scheduled liquidation rather than a spontaneous market reaction.
  • Strong Operational Metrics: The company is showing significant momentum in the entertainment and consumer discretionary sectors, evidenced by the triple-digit growth in adjusted EBITDA.
  • Revenue Outperformance: Cinemark's ability to exceed revenue estimates suggests a recovery in theater attendance or pricing power within its sector.

Risks and Uncertainties

  • Stock Price Volatility: The 8% decline in share price following the director's sale highlights potential short-term volatility for investors in the cinema and entertainment sector.
  • Earnings Sensitivity: While current results are positive, the reliance on beating consensus estimates for revenue and EBITDA remains a critical factor for maintaining market confidence.

Risks

  • The stock has experienced an 8% decline since the director's sale at $29.52, reaching $27.26.
  • Future performance depends on maintaining the momentum seen in the Q1 recovery to meet analyst price targets.

More from Insider Trading

Cheesecake Factory CEO Executes $6.3 Million Stock Sale Amid Recent Earnings Beat May 4, 2026 Option Care Health CEO Executes Substantial Common Stock Purchase Amid Recent Market Volatility May 4, 2026 Emergent BioSolutions Director Keith Katkin Executes Stock Sales and Receives New Equity Grants May 4, 2026 Emergent BioSolutions Director Executes Stock Sales Under Pre-Arranged Plan May 4, 2026 Emergent BioSolutions Director Executes Stock Sale Under Rule 10b5-1 Plan May 4, 2026